Immune Design to Present at Upcoming Investor Conferences in September
September 01, 2017 08:00 ET
|
Immune Design Corp
SEATTLE and SOUTH SAN FRANCISCO, Calif., Sept. 01, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that the company...
Immune Design Announces New CMB305 + Checkpoint Inhibitor Topline Data from an Upcoming Presentation at the ESMO 2017 Congress
August 30, 2017 18:41 ET
|
Immune Design Corp
Interim data analysis shows greater clinical benefit and immune response with CMB305+atezolizumab than with atezolizumab alone SEATTLE and SOUTH SAN FRANCISCO, Calif., Aug. 30, 2017 (GLOBE...
Immune Design Reports Second Quarter 2017 Financial Results and Provides Corporate Update
August 02, 2017 16:02 ET
|
Immune Design Corp
SEATTLE and SOUTH SAN FRANCISCO, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today reported financial results and a...
Immune Design to Report Second Quarter 2017 Financial Results & Provide Corporate Update
July 26, 2017 08:00 ET
|
Immune Design Corp
SEATTLE and SOUTH SAN FRANCISCO, Calif., July 26, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that it will report...
Immune Design Updates Positive Data from Lead Cancer Immunotherapy Programs at ASCO Annual Meeting
June 05, 2017 08:00 ET
|
Immune Design Corp
Observed median overall survival for sarcoma patients treated in two separate Phase 1 studies with an NY-ESO-1 targeted novel immunotherapy meaningfully exceeds standard of care benchmarksIn...
Immune Design to Present at Jefferies 2017 Global Healthcare Conference
June 01, 2017 08:00 ET
|
Immune Design Corp
SEATTLE and SOUTH SAN FRANCISCO, Calif., June 01, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that Carlos Paya,...
New Clinical and Biomarker Data Validate Immune Design’s Lead Programs and Discovery Platforms
May 17, 2017 16:35 ET
|
Immune Design Corp
Data from CMB305 and G100 to be Presented at ASCO Annual Meeting in June 2017 SEATTLE and SOUTH SAN FRANCISCO, May 17, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage...
Immune Design Reports First Quarter 2017 Financial Results and Provides Corporate Update
May 17, 2017 16:30 ET
|
Immune Design Corp
SEATTLE and SOUTH SAN FRANCISCO, May 17, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today reported financial results and a...
Immune Design to Report First Quarter 2017 Financial Results & Provide Corporate Update
May 08, 2017 08:00 ET
|
Immune Design Corp
SEATTLE and SOUTH SAN FRANCISCO, Calif., May 08, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that it will report...
Immune Design Announces Presentations at the 2017 ASCO Annual Meeting
April 20, 2017 11:00 ET
|
Immune Design Corp
SEATTLE and SOUTH SAN FRANCISCO, Calif., April 20, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today announced that new and...